STAR-T Cell Therapy for Resistant Autoimmune Blood Disorders
Part of Blood & lymphatic, Immune system & allergy clinical trials.
This Phase 1 trial tests a new cell therapy (STAR-T cells) for patients with autoimmune diseases like lupus or Sjögren's syndrome that have caused severe low platelet counts and haven't responded to standard treatments. The therapy may help your immune system stop attacking your platelets.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18–65 years old
- You have a diagnosed connective tissue disease (like lupus, Sjögren's syndrome, or related autoimmune condition)
- You have severe low platelet counts caused by your autoimmune disease
- Standard treatments (steroids or immunosuppressive drugs) have not worked or you can't tolerate them
- Your liver, kidney, and bone marrow function are adequate
- You are willing to use contraception for 12 months after treatment and have no active infections, hepatitis, HIV, or recent cancer
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new CAR-T cell treatment called Inaticabtagene Autoleucel for people with lupus that causes very low platelet counts (immune thrombocytopenia) that hasn't gotten better with standard treatments. The goal is to see if it can help raise platelet levels.
This trial tests a new type of cell therapy (YTS109 cells) for people with severe lupus that hasn't been controlled by standard treatments. The goal is to see if these cells can help calm the immune system and improve lupus symptoms.
This trial tests a new type of immune therapy called CAR T-cells that target two markers on your B cells (CD19 and BCMA). It is for people with certain autoimmune diseases that have not improved or have come back after standard treatments. The goal is to see if this therapy can help control the disease.
This trial tests a special type of cell therapy (CAR T-cells) that targets two markers on immune cells, CD19 and BCMA, to calm overactive immune systems in people with certain autoimmune diseases. It's for those whose disease has not been controlled by standard treatments.
This trial tests a personalized cell therapy (CAR-T) that targets a protein called CD19 on immune cells. It's for people with certain autoimmune diseases like lupus or scleroderma that are still active despite standard treatments. The goal is to see if this therapy can help control the disease when other options haven't worked.
This trial tests a new treatment using your own immune cells (called CAR-T cells) designed to target and attack cells that cause autoimmune diseases. It is for people with lupus, Sjögren's syndrome, inflammatory myopathy, scleroderma, Behcet's disease, ANCA-associated vasculitis, IgG4-related disease, antiphospholipid syndrome, or thrombotic thrombocytopenic purpura who have not improved with standard therapies.
Hear when a new Immune Thrombocytopenia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.